Pricing and reimbursement will be at the center of the transformation of the U.S. pharmaceutical industry at least through 2025. New disruptive technologies and innovations are enabling the redefinition of drug pricing and reimbursement.—in the process, redefining the very definition of what pharmaceutical companies sell and how they are organized over the next ten years.
The increasing depth and velocity of change is being fueled by the unprecedented convergence of technologies and innovation enabling disruptive: 1) reimbursement models, 2) provider business models, 3) payer consolidation, and 7) technology-enabled consumerism. As a result, the U.S. Pharmaceutical industry structure will be energized by shifts in risk sharing and patient involvement.
The $7,499.00 14th Edition of MMC’s Trends Shaping U.S. Pharmaceutical Industry Strategies report, which updates and extends the analysis of the 13th Edition*, is a fact-based presentation and analyses of the implications of the unprecedented, disruptive healthcare industry change on U.S. pharmaceutical companies, drug pricing, and strategic and operational plans between now and 2025.
By Award Winning Author and Healthcare Industry Expert Edmund L. Valentine
Report Brochure And Order Form
Click below to download a pdf of the Trends Shaping U.S. Pharmaceutical Industry Strategies report brochure and Order Form.
For more information or to discuss a Board of Directors and/or senior management briefing, a strategic or marketing workshop, or a presentation related to the Trends report, contact Ed Valentine at 203-961-9352 or firstname.lastname@example.org.